Friday, February 20, 2026

CBS renews lease at Center City Philadelphia office building

 By Samuel Murch CoStar Research

CBS recently renewed its office lease at 1500 Spring Garden St., a Class A office building in Philadelphia's Center City.

The broadcast network signed a long-term renewal for 74,000 square feet, which includes 62,000 square feet on the sixth floor and an additional 12,000 square feet in the lower level, which the company uses to support its vehicle fleet.

The broadcaster operates its Philadelphia television stations, including KYW-TV (CBS 3) and WPSG-TV (Philly 57), from the Center City location. The facility serves as its main broadcasting hub, with high-definition studios, control rooms and rooftop satellite dishes for producing and transmitting local television broadcasts and programming for the Delaware Valley. CBS originally moved into the building in 2007, and the renewal extends its term through 2042.

The large office building totals approximately 1.22 million square feet, and is jointly owned by New York-based commercial real estate investment firm Nightingale Properties and asset manager Wafra Inc.

CBS is the third-largest tenant in the building after privately held defense contractor Day & Zimmermann and casino tech firm Evolution Gaming.

www.omegare.com

PCCP acquires 1.2 million-square-foot industrial facility near Harrisburg

By Rachel Whaley with CoStar AI

PCCP, a real estate finance and investment management firm focused on commercial real estate debt and equity investments with approximately $29.2 billion in assets under management on behalf of institutional investors, acquired the Ritner Logistics Center, a 1.2 million-square-foot industrial facility fully occupied by Newell Brands in Newville, Pennsylvania, from EQT Real Estate.

Located within Pennsylvania's I-81 corridor, the building traded for $141.6 million, or about $116.52 per square foot.

Built in 2019, the distribution center at 3419 Ritner Hwy encompasses 1,215,240 square feet on a 93.17-acre site and is fully leased by Newell Brands, a Fortune 500 manufacturer and distributor of consumer and commercial products. The cross-dock configured warehouse is located less than two miles from Interstate 81, with connectivity to both I-78 and I-76.

"Central Pennsylvania is an established bulk industrial market given its proximity to dense Northeast population centers, deep and accessible labor pool, and highway connectivity," said Lia Barsanti, a senior vice president with PCCP, in a statement announcing the acquisition. "PCCP believes acquiring a 100% leased warehouse at a meaningful discount to replacement cost in a core industrial node created a strong investment opportunity for our firm."

According to PCCP, the location allows for direct access to approximately 50% of the U.S. population and 60% of the Canadian population within a one-day truck drive. It's also within a three-hour drive from major distribution nodes, including the Port of New York/New Jersey, the Port of Philadelphia, Newark Liberty International Airport, and Philadelphia International Airport.

CoStar confirmed that the property was sold in October 2020, shortly after it was completed, for $85 million, which equated to about $70 per square foot at that time.

The acquisition adds to PCCP's industrial portfolio, which now includes 70 properties totaling more than 12 million square feet, or nearly a quarter of the company's total property holdings.

www.omegare.com

Wednesday, February 18, 2026

Johnson & Johnson to build $1B cell therapy manufacturing plant in Montgomery County

 By John George – Senior Reporter, Philadelphia Business Journal

Johnson & Johnson unveiled plans Wednesday to build a more than $1 billion cell therapy manufacturing plant in Montgomery County.

The plant will be built on a 154-acre property at 1201 Sumneytown Pike in Spring House, Lower Gwynedd Township. The site is about a mile from Johnson & Johnson's 171-acre research and development campus in Spring House. That campus, at McKean and Welsh roads, houses about 2,500 employees.

The Sumneytown Pike site for the new manufacturing plant has an existing 157,000-square-foot building but is otherwise undeveloped. It was sold by Gwynedd Mercy University for $31.5 million in 2022 to Beacon Capital Partners, a Boston real estate investment firm that owns the nearby Spring House Innovation Park. Johnson & Johnson (NYSE: JNJ) said it would own and develop the property, and the existing building at the site will be torn down.

The project is part of Johnson & Johnson's previously announced plan to invest $55 billion by early 2029 to manufacture the "vast majority" of its advanced medicines, including cell therapies that use living and modified cells to treat disease, in the United States.

“By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families," Joaquin Duato, CEO of Johnson & Johnson, said in a statement.

The state is providing a $41.5 million economic package to support the Johnson & Johnson project. That package includes up to $12 million in tax credits through Pennsylvania's Qualified Manufacturing Innovation and Reinvestment Deduction program, up to $2 million in tax credits through the state's Manufacturing Tax Credit program, a $15 million grant through the Pennsylvania Strategic Investments to Enhance Sites program and a $10 million Pennsylvania First grant.

The state has also committed to providing a Redevelopment Assistance Capital Program award of up to $2.5 million to a local community college or technical school to help create a workforce development training program that would serve as a talent pipeline for the company in Montgomery County.

In a statement, Rick Siger, secretary of the Pennsylvania Department of Community and Economic Development, called Johnson & Johnson's decision to reinvest in Montgomery County "another huge win" for the state that further expands its life sciences ecosystem.

Gov. Josh Shapiro said in a statement that the project is further proof Pennsylvania is emerging as a "powerhouse" for innovation and manufacturing in the life sciences.

Johnson & Johnson is not disclosing the square footage of the Spring House plant, which it said will expand its manufacturing capacity as it advances its portfolio and pipeline of cell therapy medicines for cancer, immune-mediated and neurological diseases. The company has one cell therapy, Carvykti, approved by the Food and Drug Administration. The medicine is used to treat relapsed or refractory multiple myeloma.

Johnson & Johnson previously operated its Spring House campus as a Janssen Research & Development site. The company started phasing out the Janssen Pharmaceuticals name in 2023 as part of a corporate rebranding. Johnson & Johnson still maintains Janssen Biotech in neighboring Horsham, and the division will operate the new Spring House plant.

Full story: https://www.bizjournals.com/philadelphia/news/2026/02/18/johnson-johnson-cell-therapy-spring-house.html

www.omegare.com

Tuesday, February 17, 2026

AI Hits Disruption in Commercial Real Estate (Video)

Real Estate & Economic Outlook with Ryan Severino (Video)

www.omegare.com

Cencora Philadelphia headquarters hits market in test of improving office values

 By Katie Burke CoStar News

A Philadelphia-area office property anchored by a pharmaceutical giant was what drove PRP Real Assets to scoop it up. Now, the national investment firm is testing how far the market has come since the COVID-19 pandemic with its move to list the fully leased building for sale.

The Washington, D.C.-based investor is on the hunt for a buyer for the more than 429,120-square-foot building at 1 W. First Ave. in Conshohocken, Pennsylvania. The 11-story property was developed in the earlier years of the pandemic as a built to suit for Cencora, the pharmaceutical distributor that occupies its entirety to house its corporate headquarters.

The building, completed in 2021, serves as an anchor for the Sora West district, the mixed-use project spearheaded through a joint venture between local developer Keystone Property Group and the Montgomery County Redevelopment Authority in an effort to create a more walkable and mixed-use environment for the Philadelphia suburb.

The more than 1,500 people who commute to Cencora's corporate hub have access not only to the property's fitness and wellness amenities, on-site dining outposts, corporate event space and various lounges, but also to the broader development's hotel, outdoor event space and proximity to Center City Philadelphia.

PRP acquired an 89% stake in the Cencora headquarters building in early 2021 for $340 million alongside equity partner Riyad Capital. Pricing for the listing has not been publicly disclosed.

All about timing

The listing hits at a point when capital markets, long frozen by the residual impacts of the pandemic, are quickly heating back up.

The national vacancy rate of about 14% has largely hit its peak, according to CoStar research. While U.S. office leasing has yet to fully recover to pre-pandemic levels, the 12 million square feet of deals signed in the third quarter is the most since 2019.

Improving market dynamics has meant sellers are betting on their chances of landing higher prices for their properties, and a growing pool of large office landlords and investment firms is on the hunt for listings aimed at strengthening their spots at the forefront of the office market recovery blooming across the United States.

All of that has collided to create a sense of urgency and competition for attractive listings. To be clear, that attention has largely been concentrated on properties in the most desirable locations, which already include an attractive bevy of amenities or come with a solid tenant roster.

PRP is betting the Sora West office property will deliver on it all.

The Conshohocken area, known as "Conshy" for locals, accounts for just a small slice of the greater Philadelphia office market. Its size has meant that leasing activity in the suburb is far less compared to Center City, but it has also been largely insulated from the dramatic vacancy and demand swings that have plagued the downtown Philadelphia area over the past several years, said Brenda Nguyen, CoStar's local director of market analytics.

Yet the area has also attracted a larger share of new developments, Nguyen said, helping to attract a crowd of life science and technology firms looking to take advantage of the suburb's more modern inventory and transit-oriented perks.

Office sales are few and far between — there have only been four to close over the past year — but considering its long-term deal with Cencora and the property's desirable address, PRP and its partners think it makes for a compelling investment play.

"Sora West is one of only a handful of trophy office buildings constructed in the Philadelphia market over the past five years. With no significant new development on the horizon, the property is strategically positioned as a flagship asset in the region for years to come."

www.omegare.com